A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Distinct / DIV-SCLC-301
NCT03098030
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Small Cells - Lung |
Dr. Vera Hirsh
Nicola Raby
514-934-1934 poste 34095
|
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ADRIATIC
NCT03703297
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Small Cells - Lung |
Dr. Scott Owen
Corneille Bashagaluke
514-934-1934 poste 34907
|
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients
LAGOON
NCT05153239
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Small Cells - Lung |
Dr. Scott Owen
Nicola Raby
514-934-1934 poste 34095
|
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Small Cells - Lung |
Dr. Caroline Lavoie
Josée Allard
418-525-4444 poste 16730
|
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Recruiting
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
Small Cells - Lung |
Dr. François Vincent
Marie-Ève Caron
819-697-3333 poste 63238
|
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy
MK-3475-B98/KEYNOTE-B98
NCT04938817
Recruiting
|
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY
|
Small Cells - Lung |
Dr. Adrian Langleben
Rachelle Dumas
514-345-3511 poste 3378
|
Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
EMERGE 402 (JZP712-402)
NCT04894591
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
Small Cells - Lung |
Dr. Danièle Marceau
Pierre Bédard
418-835-7121
|
Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
EMERGE 402 (JZP712-402)
NCT04894591
Recruiting
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Small Cells - Lung |
Dr. José Luiz Miranda Guimaraes
Pascale Duchesne
418-541-1000 poste 2840
|
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
20200491
NCT05060016
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Small Cells - Lung |
Dr. Nicolas Marcoux
Marie-Pierre Brochu
418-525-4444 poste 15768
|
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients
LAGOON
NCT05153239
Recruiting
|
HOPITAL DE LA CITE-DE-LA-SANTE
|
Small Cells - Lung |
Dr. Elie Kassouf
Imane Benmouhoub
450-668-1010 poste 23671
|
Groupe d'étude en oncologie du Québec